Evidence map›Paper›PMID 39795129›Full record

ArticleMolecules (Basel, Switzerland)2024

The Diverse Binding Modes Explain the Nanomolar Levels of Inhibitory Activities Against 1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase from

Sana Takada, Mona A Abdullaziz, Stefan Höfmann, Talea Knak, Shin-Ichiro Ozawa, Yasumitsu Sakamoto, Thomas Kurz, Nobutada Tanaka

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sana TakadaSchool of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan.ORCID 0009-0006-7357-244X
Mona A AbdullazizInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.
Stefan HöfmannInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.ORCID 0000-0003-0588-6974
Talea KnakInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.
Shin-Ichiro OzawaSchool of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan.ORCID 0000-0001-7350-2069
Yasumitsu SakamotoSchool of Pharmacy, Iwate Medical University, Yahaba, Morioka 028-3694, Japan.ORCID 0000-0003-1067-954X
Thomas KurzInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.ORCID 0000-0002-9474-4224
Nobutada TanakaSchool of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan.ORCID 0000-0001-5365-4698

Funding

Deutsche Forschungsgemeinschaft GRK2158Heiwa Nakajima Foundation noneJapan Society for the Promotion of Science 120223508
6 · The paper itself

Abstract

It is established that reverse hydroxamate analogs of fosmidomycin inhibit the growth of

Indexed as

Aldose-Ketose IsomerasesAntimalarialsEnzyme InhibitorsFosfomycinHydroxamic AcidsOxidoreductasesPlasmodium falciparumCatalytic DomainCrystallography, X-RayHumansModels, MolecularProtein BindingStructure-Activity Relationship1-deoxy-D-xylulose 5-phosphate reductoisomeraseAldose-Ketose IsomerasesAntimalarialsEnzyme InhibitorsFosfomycinfosmidomycinHydroxamic AcidsOxidoreductasescrystal structureDXRfosmidomycinIspCmalaria

Identifiers

PMID39795129
PMCPMC11721986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.